Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Direct thrombin inhibitors.

Karen L Kaplan1

  • 1Hematology-Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 610, Rochester, NY 14642, USA. karen_kaplan@urmc.rochester.edu

Expert Opinion on Pharmacotherapy
|May 13, 2003
PubMed
Summary
This summary is machine-generated.

Direct thrombin inhibitors represent a novel class of antithrombotic medications. This review examines their mechanisms, pharmacokinetics, and clinical applications, contrasting them with traditional anticoagulants.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous thromboembolism in patients with diffuse large B-cell lymphoma.

Leukemia & lymphomaยท2006
Same author

What does cerebral platelet activation mean in the setting of carotid stenosis?

Neurologyยท2006
Same author

Nicardipine versus nitroprusside for deliberate hypotension during idiopathic scoliosis repair.

Journal of clinical anesthesiaยท2004
Same author

Patients with inferior vena caval filters should receive chronic thromboprophylaxis.

The Medical clinics of North Americaยท2003
Same author

De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.

American journal of kidney diseases : the official journal of the National Kidney Foundationยท2003
Same author

Direct thrombin inhibitors.

Seminars in hematologyยท2002
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapyยท2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapyยท2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapyยท2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapyยท2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapyยท2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapyยท2026
See all related articles

Area of Science:

  • Pharmacology
  • Biochemistry
  • Medicine

Background:

  • Antithrombotic therapy is crucial for managing thromboembolic disorders.
  • Traditional anticoagulants include heparin derivatives and warfarin-type drugs.
  • Direct thrombin inhibitors offer a new therapeutic approach by directly targeting thrombin.

Purpose of the Study:

  • To review the emerging class of direct thrombin inhibitors.
  • To discuss their chemical structures, inhibition kinetics, and pharmacokinetic profiles.
  • To evaluate their current and potential clinical applications.

Main Methods:

  • Literature review of direct thrombin inhibitors.
  • Analysis of published data on chemical properties and biological activity.
  • Synthesis of information on pharmacokinetics and clinical trial outcomes.

Main Results:

  • Direct thrombin inhibitors bind to thrombin, blocking its enzymatic activity.
  • Approved agents include lepirudin, desirudin, bivalirudin, and argatroban.
  • Melagatran/ximelagatran is a promising agent in advanced clinical development.

Conclusions:

  • Direct thrombin inhibitors represent a significant advancement in antithrombotic drug development.
  • Understanding their specific properties is key to optimizing their clinical use.
  • Further research will continue to define their role in anticoagulation therapy.